Abstract:
Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.
Abstract:
Compounds of formula (I) are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
Abstract:
Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
Abstract:
Compounds of formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, wherein R1 is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocycle, heterocyclealkyl, heteroaryl, or heteroarylalkyl; R4 is formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (Ie) or formula (If); or formula (II), or a pharmaceutically acceptable salt, amide, ester or prodrug thereof, wherein R14 is formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), or formula (XII); modulate PN3 in mammals and are useful in treating pain in mammals.
Abstract:
Compounds of formula (I), are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
Abstract:
Compounds of formula (I), are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
Abstract:
OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES ARE USEFUL IN TREATING CONDITIONS OR DISORDERS PREVENTED BY OR AMELIORATED BY HISTAMINE-3 RECEPTOR LIGANDS. OCTAHYDRO PYRROLO[3,4-B]PYRROLE COMPOUNDS, METHODS FOR USING SUCH COMPOUNDS, COMPOSITIONS FOR MAKING THEM, AND PROCESSES FOR PREPARING SUCH COMPOUNDS ARE DISCLOSED HEREIN.
Abstract:
Disclosed are 1-phenyl-pyrrolo[3,4-b]pyrrole derivatives as represented by the general formula (I), wherein R1 is alkyl, cycloalkyl, or (cycloalkyl)methyl; R2a-R2f each are independently hydrogen, methyl, or fluoromethyl; R3a-R3d are each independently hydrogen, alkyl, fluoroalkyl, fluoroalkoxy, alkoxy, thioalkoxy, halogen, or nitrile; L1 is a bond, oxygen, sulfur, carbonyl, alkylene, alkylcarbonyl, alkylamino, -C(=N-Oalkyl)-, or NR4; L2 is a bond, oxygen, sulphur, carbonyl, alkylene, alkylcarbonyl, alkylamino, -C(=N-Oalkyl)-, NR5, -C(=O)NR5-, or -NR5C(=O)-; Cy1 is aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; Cy2 is aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycle, wherein the heteroaryl or heterocycle moiety has 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, provided that at least one heteroatom is nitrogen; and wherein the other substituents are as defined herein. Of particular importance are the compounds 2-{ 4'-[(3aR,6aR)-5- methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]-1,1'-biphenyl-4-yl} pyridazin-3(2H)-one, 2-(5-{ 4-[(3aR,6aR)-5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]phenyl} pyridin-2-yl)pyridazin-3(2H)-one and 2-(6-{ 4-[(3aR,6aR)-5-methylhexahydropyrrolo[3,4-b]pyrrol-1(2H)-yl]phenyl} pyridin-3-yl)pyridazin-3(2H)-one. Further disclosed is a harmaceutical composition which comprises a compound as defined above and a pharmaceutically acceptable carrier.